Results 171 to 180 of about 19,227 (236)
Avoidance versus use of neuromuscular blocking agents for optimizing video laryngoscopy-assisted tracheal intubation: A protocol for a systematic review with meta-analysis and trial sequential analysis. [PDF]
Acta Anaesthesiol ScandCreutzburg A +7 more
europepmc +1 more source
Experimental Physiology, Volume 111, Issue 10, Page 4286-4295, 1 October 2026.Abstract Repurposing clinically approved antifibrotic agents presents a potential near‐term therapeutic strategy to mitigate the extensive fibrotic scarring that follows severe volumetric muscle loss (VML) injury and inhibits functional recovery. We hypothesized that daily oral administration of pirfenidone, an FDA‐approved antifibrotic, would mitigate
Jessica M. Motherwell +4 more
wiley +1 more source
Management of Neuromuscular Blocking Agents in Critically Ill Patients with Lung Diseases. [PDF]
J Clin MedIavarone IG +6 more
europepmc +1 more source
Adverse events related to neuromuscular blocking agents: a disproportionality analysis of the FDA adverse event reporting system. [PDF]
Front PharmacolLi L, Xu Q, Liu Y, Pang L, Cui Z, Lu Y.
europepmc +1 more source
Early neuromuscular blocking agents for adults with acute respiratory distress syndrome: a systematic review, meta-analysis and meta-regression. [PDF]
BMJ Open, 2020 Shao S, Kang H, Tong Z.
europepmc +1 more source
Current use of neuromuscular blocking agents and antagonists in Korea: a 2018 survey. [PDF]
Anesth Pain Med (Seoul), 2019 Kim JS +8 more
europepmc +1 more source